Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
about
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnTreatment of rheumatic diseases and hepatitis B virus coinfectionComparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort studyHerpes simplex virus encephalitis during treatment with etanercept.Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.The use of biologic DMARDs identifies rheumatoid arthritis patients with more optimistic expectations of total knee arthroplasty.Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesLLLT for the management of patients with ankylosing spondylitis.Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysisB lymphocyte-typing for prediction of clinical response to rituximab.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting"Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Biologics in oral medicine: principles of use and practical considerations.Biologics in oral medicine: ulcerative disorders.Biologics in oral medicine: Sjogren syndrome.Trends in rheumatic fever: clinical aspects and perspectives in prophylactic treatments.Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals.Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.Evolution of treatment for rheumatoid arthritis.Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence.Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.
P2860
Q26862017-BDEE9400-F5DA-4E66-95F7-DC1A4490294BQ28084305-44F749D4-AA09-4ECA-8F18-74F5A5265A0EQ28542423-094DBA45-629A-43FC-B191-14FB4D7A58F8Q30694936-55F3CF1D-6E3F-4AD1-B3CB-33C4E938B9FBQ30731527-A2ECC024-1327-4BE2-94F2-6FFF0BB0E390Q33808559-76DBA6F2-29E6-4FBD-A2F7-D1F20B548B47Q35863952-983771D2-F68C-4FC2-A3E5-456970A52D10Q35900547-B07B4942-9B4E-41EA-B5D2-D91B10F7FA8EQ36133890-4E4B7828-0664-4996-8DFC-719124782DE5Q36220823-1FB42107-71A2-4711-88F8-0190296D9F65Q36633292-092A54A4-061B-49A9-9050-7352FFFE09A5Q36677277-65AA78A4-C1F1-4DEB-AD67-5739BFE9C9A3Q37023883-5C662EF0-E7FD-46B2-945B-DAE1E4E3EA5AQ37221862-2751B9FF-C3C4-4D4D-BB90-AFA0199218A1Q37343166-B8708AB9-CE43-43E4-9E61-B8C12D35A4F1Q37358271-04DC230B-511B-44DE-BC79-260D0264B003Q37993932-E5DA0842-DF02-4AA2-B13C-04E6EF992E67Q37999475-7ABC23DD-D4AA-412C-8526-91744AEA9A6AQ38002156-5057AAB4-DEDF-451E-9C26-6BFA7E71B97BQ38020883-B191566B-FB54-4145-B777-49A7C268B20EQ38046653-329ACEC6-EA75-400C-97B4-2B397079AF85Q38063585-34F0DE91-7750-4CE2-BAA0-8A0AABF4FF16Q38065767-BCB68BB0-2F35-49C0-B8CB-7AF500658297Q38411930-DF6AED13-6533-4648-A244-E45008226139Q38437185-5B537C6D-323A-4766-A598-351CA0BC0C0CQ42578542-7AB0B5C0-F6B0-47AA-95B6-C2BCADCCB88CQ44992977-2E08706B-DA73-431C-BD21-B93C478E70F6
P2860
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@en
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@en-gb
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@nl
type
label
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@en
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@en-gb
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@nl
prefLabel
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@en
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@en-gb
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@nl
P2093
P50
P356
P1476
Updated consensus statement on ...... t of rheumatic diseases, 2010.
@en
P2093
A Gibofsky
A Kavanaugh
E C Keystone
F C Breedveld
F De Benedetti
J R Kalden
J S Smolen
P356
10.1136/ARD.2010.146852
P407
P478
70 Suppl 1
P577
2011-03-01T00:00:00Z